MECO & UGEnome Case study | bone metastasis risk in breast cancer treatment

Zachary Brooks
November 9, 2023
1:46 pm
#biochemistry, #bioinfo, #bioinformatics, #biologist, #biology, #biostatistics, #biotech, #biotechnologist, #biotechnology, #chemistry, #datascience, #dna, #genetics, #genomics, #health, #immunology, #lifesciences, #medicine, #microbiology, #pharma, #pharmacogenetics, #pharmacogenomics, #research, #science, #scientist, #ugenome, #ugenomebiotech

UGenome provides bioinformatics services in medical assessment for breast cancer treatment

Background

Fibrotic-like matrix stiffness pro- motes distinct metastatic phenotypes in cancer cells, which are preserved after transition to softer microen- vironments, such as bone marrow.
Using differential gene expression analysis a score of mechanical conditioning (MeCo) associated with bone metastasis in patients with breast cancer.

Watson, A. W., Grant, et al. (2021). Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell reports.

UGenome’s service

Client had access to RNA-seq data from breast cancer patients before treatment with Nintenab* UGenome pre-processed and aligned the RNA-seq data to a reference genome. UGenome converted the aligned RNA-seq data to transcripts per million and calculated a MeCo score for each patient. *Nintedanib is used to treat idiopathic pulmonary fibrosis

Highlights

Using bioinformatics analyses can create scores to help detect disease progression and treatment quicker
Clinicians can use additive scoring as a tool to help their patients receive personalized treatment
Patients can have better outcomes with precision information about their fight against cancer

Use the Contact form for more information

https://ugenomebiotech.com/contact-us/